<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35430734</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-1746</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of gastroenterology and hepatology</Title>
          <ISOAbbreviation>J Gastroenterol Hepatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.15853</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Balloon-occluded retrograde transvenous obliteration (BRTO) is widely performed for treating gastric varices (GVs). However, worsening of esophageal varices (EVs) can be observed after BRTO. This study aimed to investigate the impact of EV worsening on prognosis after BRTO.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Overall, 258 patients who underwent initial BRTO for GV treatment between January 2004 and May 2019 at 12 institutions were retrospectively registered.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Technical success was achieved in 235 patients (91.1%). Based on the exclusion criteria, 37 patients were excluded, and 198 were evaluated. The cumulative worsening rates of EVs at 1, 2, and 3 years were 39.0%, 59.4%, and 68.4%, respectively. In the univariate Cox proportional hazards model, sex, EV size, history of EV treatment, left gastric vein dilatation, platelet count, aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, albumin-bilirubin score, prothrombin time-international normalized ratio, fibrosis-4 index, AST to platelet ratio index, and spleen width were significantly associated with worsening of EV after BRTO. Multivariate analysis showed that sex (adjusted hazard ratio [aHR] 1.72; 95% confidence interval [CI] 1.03-2.86; P = 0.04), left gastric vein dilatation (aHR 1.90; 95% CI 1.17-3.10; P = 0.01), ALT (aHR 1.01; 95% CI 1.00-1.03; P = 0.02), albumin (aHR 0.61; 95% CI 0.43-0.87; P &lt; 0.01), and spleen width (aHR 1.02; 95% CI 1.01-1.03; P &lt; 0.01) were independent risk factors for worsening of EV after BRTO. Patients with EV worsening within 1 year after BRTO had a significantly worse prognosis than the other patients (P = 0.007).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early worsening of EV after BRTO was associated with poor prognosis after BRTO.</AbstractText>
          <CopyrightInformation>© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shinkai</LastName>
            <ForeName>Kazuma</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakamori</LastName>
            <ForeName>Ryotaro</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-1580-607X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamada</LastName>
            <ForeName>Ryoko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tahata</LastName>
            <ForeName>Yuki</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-9116-7054</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nozaki</LastName>
            <ForeName>Yasutoshi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Kansai Rosai Hospital, Amagasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Kengo</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Toyonaka Municipal Hospital, Toyonaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tawara</LastName>
            <ForeName>Seiichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Osaka General Medical Center, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuda</LastName>
            <ForeName>Kazuto</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Ikeda Municipal Hospital, Ikeda, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Yuichi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Suita Municipal Hospital, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Hospital Organization Osaka National Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ito</LastName>
            <ForeName>Toshifumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doi</LastName>
            <ForeName>Yoshinori</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>KKR Otemae Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iio</LastName>
            <ForeName>Sadaharu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakakibara</LastName>
            <ForeName>Mitsuru</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Yao Municipal Hospital, Yao, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakanishi</LastName>
            <ForeName>Fumihiko</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kodama</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-6250-1324</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hikita</LastName>
            <ForeName>Hayato</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-2488-7315</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tatsumi</LastName>
            <ForeName>Tomohide</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takehara</LastName>
            <ForeName>Tetsuo</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-5036-3457</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>J Gastroenterol Hepatol</MedlineTA>
        <NlmUniqueID>8607909</NlmUniqueID>
        <ISSNLinking>0815-9319</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BRTO</Keyword>
        <Keyword MajorTopicYN="N">gastric varices</Keyword>
        <Keyword MajorTopicYN="N">liver cirrhosis</Keyword>
        <Keyword MajorTopicYN="N">portal hypertension</Keyword>
        <Keyword MajorTopicYN="N">spleen size</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>21</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430734</ArticleId>
        <ArticleId IdType="doi">10.1111/jgh.15853</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992; 16: 1343-1349. https://doi.org/10.1002/hep.1840160607</Citation>
        </Reference>
        <Reference>
          <Citation>Mumtaz K, Majid S, Shah HA et al. Prevalence of gastric varices and results of sclerotherapy with N-butyl 2 cyanoacrylate for controlling acute gastric variceal bleeding. World J. Gastroenterol. 2007; 13: 1247-1251. https://doi.org/10.3748/wjg.v13.i8.1247</Citation>
        </Reference>
        <Reference>
          <Citation>Hong CH, Kim HJ, Park JH et al. Treatment of patients with gastric variceal hemorrhage: endoscopic N-butyl-2-cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration. J. Gastroenterol. Hepatol. 2009; 24: 372-378. https://doi.org/10.1111/j.1440-1746.2008.05651.x</Citation>
        </Reference>
        <Reference>
          <Citation>Saad WE, Darcy MD. Transjugular intrahepatic portosystemic shunt (TIPS) versus balloon-occluded retrograde transvenous obliteration (BRTO) for the management of gastric varices. Semin. Intervent. Radiol. 2011; 28: 339-349. https://doi.org/10.1055/s-0031-1284461</Citation>
        </Reference>
        <Reference>
          <Citation>Ninoi T, Nishida N, Kaminou T et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am. J. Roentgenol. 2005; 184: 1340-1346. https://doi.org/10.2214/ajr.184.4.01841340</Citation>
        </Reference>
        <Reference>
          <Citation>Watanabe M, Shiozawa K, Ikehara T et al. Short-term effects and early complications of balloon-occluded retrograde transvenous obliteration for gastric varices. ISRN Gastroenterol. 2012; 2012: 919371. https://doi.org/10.5402/2012/919371</Citation>
        </Reference>
        <Reference>
          <Citation>Sonomura T, Ono W, Sato M et al. Three benefits of microcatheters for retrograde transvenous obliteration of gastric varices. World J. Gastroenterol. 2012; 18: 1373-1378. https://doi.org/10.3748/wjg.v18.i12.1373</Citation>
        </Reference>
        <Reference>
          <Citation>Luo X, Xiang T, Wu J et al. Endoscopic cyanoacrylate injection versus BRTO for prevention of gastric variceal bleeding: a randomized controlled trial. Hepatology 2021; 74: 2074-2084. https://doi.org/10.1002/hep.31718</Citation>
        </Reference>
        <Reference>
          <Citation>Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J. Vasc. Interv. Radiol. 2001; 12: 327-336. https://doi.org/10.1016/S1051-0443(07)61912-5</Citation>
        </Reference>
        <Reference>
          <Citation>Akahoshi T, Hashizume M, Tomikawa M et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J. Gastroenterol. Hepatol. 2008; 23: 1702-1709. https://doi.org/10.1111/j.1440-1746.2008.05549.x</Citation>
        </Reference>
        <Reference>
          <Citation>Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J. Gastroenterol. Hepatol. 1996; 11: 51-58. https://doi.org/10.1111/j.1440-1746.1996.tb00010.x</Citation>
        </Reference>
        <Reference>
          <Citation>Tajiri T, Yoshida H, Obara K et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig. Endosc. 2010; 22: 1-9. https://doi.org/10.1111/j.1443-1661.2009.00929.x</Citation>
        </Reference>
        <Reference>
          <Citation>Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N. Engl. J. Med. 1999; 340: 988-993. https://doi.org/10.1056/NEJM199904013401302</Citation>
        </Reference>
        <Reference>
          <Citation>Lay CS, Tsai YT, Teg CY et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997; 25: 1346-1350. https://doi.org/10.1002/hep.510250608</Citation>
        </Reference>
        <Reference>
          <Citation>Maruyama H, Kobayashi K, Kiyono S et al. Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance. Clin. Transl. Gastroenterol. 2018; 9: 154. https://doi.org/10.1038/s41424-018-0021-8</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou HY, Chen TW, Zhang XM et al. Diameters of left gastric vein and its originating vein on magnetic resonance imaging in liver cirrhosis patients with hepatitis B: association with endoscopic grades of esophageal varices. Hepatol. Res. 2014; 44: E110-E117. https://doi.org/10.1111/hepr.12246</Citation>
        </Reference>
        <Reference>
          <Citation>Groszmann RJ, Garcia-Tsao G, Bosch J et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 2005; 353: 2254-2261. https://doi.org/10.1056/NEJMoa044456</Citation>
        </Reference>
        <Reference>
          <Citation>Merli M, Nicolini G, Angeloni S et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J. Hepatol. 2003; 38: 266-272. https://doi.org/10.1016/S0168-8278(02)00420-8</Citation>
        </Reference>
        <Reference>
          <Citation>Choi YS, Lee JH, Sinn DH et al. Effect of balloon-occluded retrograde transvenous obliteration on the natural history of coexisting esophageal varices. J. Clin. Gastroenterol. 2008; 42: 974-979. https://doi.org/10.1097/MCG.0b013e318126c154</Citation>
        </Reference>
        <Reference>
          <Citation>Jogo A, Nishida N, Yamamoto A et al. Factors associated with aggravation of esophageal varices after B-RTO for gastric varices. Cardiovasc. Intervent. Radiol. 2014; 37: 1243-1250. https://doi.org/10.1007/s00270-013-0809-6</Citation>
        </Reference>
        <Reference>
          <Citation>Elsamman MK, Fujiwara Y, Kameda N et al. Predictive factors of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration in patients with gastric varices. Am. J. Gastroenterol. 2009; 104: 2214-2221. https://doi.org/10.1038/ajg.2008.140</Citation>
        </Reference>
        <Reference>
          <Citation>Mizutani T, Nirei K, Kanda T et al. Left gastric vein width is an important risk factor for exacerbation of esophageal varices post balloon-occluded retrograde transvenous obliteration for gastric varices in cirrhotic patients. Medicina (Kaunas) 2022; 58: 205. https://doi.org/10.3390/medicina58020205</Citation>
        </Reference>
        <Reference>
          <Citation>Giannini E, Botta F, Borro P et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of esophageal varices in patients with liver cirrhosis. Gut 2003; 52: 1200-1205. https://doi.org/10.1136/gut.52.8.1200</Citation>
        </Reference>
        <Reference>
          <Citation>Madhotra R, Mulcahy HE, Willner I, Reuben A. Prediction of esophageal varices in patients with cirrhosis. J. Clin. Gastroenterol. 2002; 34: 81-85. https://doi.org/10.1097/00004836-200201000-00016</Citation>
        </Reference>
        <Reference>
          <Citation>Berzigotti A, Seijo S, Arena U et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144: 102-111. https://doi.org/10.1053/j.gastro.2012.10.001</Citation>
        </Reference>
        <Reference>
          <Citation>Goral V, Yılmaz N. Current approaches to the treatment of gastric varices: glue, coil application, TIPS, and BRTO. Medicina (Kaunas) 2019; 55: 335. https://doi.org/10.3390/medicina55070335</Citation>
        </Reference>
        <Reference>
          <Citation>Waguri N, Osaki A, Watanabe Y. Balloon-occluded retrograde transvenous obliteration for treatment of gastric varices. World J. Hepatol. 2021; 13: 650-661. https://doi.org/10.4254/wjh.v13.i6.650</Citation>
        </Reference>
        <Reference>
          <Citation>Etzion O, Takyar V, Novack V et al. Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension. Hepatol Commun 2018; 2: 919-928. https://doi.org/10.1002/hep4.1198</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
